EMA/PE/0000223040
Submitted by Anonymous (not verified) on 14 October 2026 - 8:43
EMA/PE/0000223040
EMA/PE/0000183462
Submitted by Anonymous (not verified) on 14 October 2026 - 8:39
EMA/PE/0000183462
Human medicines European public assessment report (EPAR): Denosumab Ascend, denosumab, Date of authorisation: 28/08/2026, Status: Authorised
Submitted by Anonymous (not verified) on 14 October 2026 - 8:05
Human medicines European public assessment report (EPAR): Denosumab Ascend, denosumab, Date of authorisation: 28/08/2026, Status: Authorised
Qualification of novel methodologies for medicine development: CHMP qualification opinions
Submitted by Anonymous (not verified) on 13 October 2026 - 21:25
Qualification of novel methodologies for medicine development: CHMP qualification opinions
Qualification of novel methodologies for medicine development: Letters of support
Submitted by Anonymous (not verified) on 13 October 2026 - 21:20
Qualification of novel methodologies for medicine development: Letters of support
Human medicines European public assessment report (EPAR): Revatio, sildenafil, Date of authorisation: 28/10/2005, Revision: 55, Status: Authorised
Submitted by Anonymous (not verified) on 13 October 2026 - 16:33
Human medicines European public assessment report (EPAR): Revatio, sildenafil, Date of authorisation: 28/10/2005, Revision: 55, Status: Authorised
Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Date of authorisation: 05/07/2004, Revision: 73, Status: Authorised
Submitted by Anonymous (not verified) on 13 October 2026 - 16:31
Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Date of authorisation: 05/07/2004, Revision: 73, Status: Authorised
Human medicines European public assessment report (EPAR): Viagra, sildenafil, Date of authorisation: 13/09/1998, Revision: 52, Status: Authorised
Submitted by Anonymous (not verified) on 13 October 2026 - 16:30
Human medicines European public assessment report (EPAR): Viagra, sildenafil, Date of authorisation: 13/09/1998, Revision: 52, Status: Authorised
Human medicines European public assessment report (EPAR): Olumiant, baricitinib, Date of authorisation: 13/02/2017, Revision: 29, Status: Authorised
Submitted by Anonymous (not verified) on 13 October 2026 - 16:28
Human medicines European public assessment report (EPAR): Olumiant, baricitinib, Date of authorisation: 13/02/2017, Revision: 29, Status: Authorised
Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 13 October 2026 - 16:14
Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 18, Status: Authorised